Literature DB >> 6165472

Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.

S Ginsberg, J Kirshner, S Reich, L Panasci, T Finkelstein, S Fandrich, A Fitzpatrick, L Shechtman, R Comis.   

Abstract

Systemic administration of most chemotherapeutic agents has been assumed to be ineffective in the treatment of primary and metastatic brain tumors because these agents fail to cross the intact blood-brain barrier. However, agents which fail to penetrate the intact blood-brain barrier may penetrate it under conditions which include the presence of tumor in the central nervous system (CNS) and prior CNS irradiation. This paper reports the results of pharmacokinetic studies of bleomycin, cisplatin, and vinblastine in the CNS of a patient with a primary germ cell tumor of the brain who had received prior radiotherapy. Significant concentrations of bleomycin and cisplatin, but not of vinblastine, were reached in the cerebrospinal fluid (CSF) of the patient following iv administration. The area under the bleomycin CSF concentration times time curve was 25% of the area under the bleomycin plasma concentration times time curve. The areas under two cisplatin CSF curves were 50% and 155% of the areas under the corresponding free cisplatin plasma curves. Moreover, an objective response of the tumor to the chemotherapy was documented. This study provides evidence that, under certain circumstances, significant concentrations of cisplatin and bleomycin may be obtained in human CSF following systemic administration and that it may be possible to treat primary or metastatic CNS tumors with agents effective against systemic tumor of the same histologic type.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165472

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

Review 1.  Primary skull-based yolk-sac tumour: case report and review of central nervous system germ cell tumours.

Authors:  Raman Verma; Shawn Malone; Christina Canil; Gerard Jansen; Howard Lesiuk
Journal:  J Neurooncol       Date:  2010-05-26       Impact factor: 4.130

Review 2.  Chemotherapy for intramedullary spinal cord tumors.

Authors:  C Balmaceda
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

3.  Chemotherapy trials in recurrent primary intracranial germ cell tumors.

Authors:  J C Allen; G Bosl; R Walker
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

4.  Cisplatin-based chemotherapy in primary central nervous system germ cell tumors.

Authors:  S R Patel; J C Buckner; W A Smithson; B W Scheithauer; R V Groover
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

5.  Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer.

Authors:  A Gerl; C Clemm; P Kohl; A Schalhorn; W Wilmanns
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

6.  Germ cell tumor in the hypothalamo-neurohypophysial region: clinical features and treatment.

Authors:  S Nishio; T Inamura; I Takeshita; M Fukui; K Kamikaseda
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

7.  Response of a recurrent choroid plexus tumor to combination chemotherapy.

Authors:  B L Maria; M L Graham; L C Strauss; M D Wharam
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study.

Authors:  A Olivi; M Gilbert; K L Duncan; B Corden; D Lenartz; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Damage and repair of the immature rat cerebellum after cis-dichlorodiammineplatinum II (cis-DDP) treatment. An ultrastructural study.

Authors:  E Scherini; M Biggiogera; G Bernocchi; V Mares
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.

Authors:  Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.